Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia - PubMed (original) (raw)
Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia
S Erhardt et al. Neurosci Lett. 2001.
Abstract
Kynurenic acid is an endogenous glutamate antagonist with a preferential action at the glycine-site of the N-methyl D-aspartate-receptor. Mounting evidence indicate that the compound is significantly involved in basal neurophysiological processes in the brain. In the present investigation, cerebrospinal fluid (CSF) level of kynurenic acid was analyzed in 28 male schizophrenic patients and 17 male healthy controls by means of high pressure liquid chromatography and fluorescence detection. Schizophrenic patients showed elevated CSF levels of kynurenic acid (1.67+/-0.27 nM) compared to the control group (0.97+/-0.07 nM). Furthermore, CSF levels of kynurenic acid in schizophrenic patients were also found to correlate with age. The present finding is indicative of a contribution of kynurenic acid in the pathogenesis of schizophrenia.
Similar articles
- The kynurenic acid hypothesis of schizophrenia.
Erhardt S, Schwieler L, Nilsson L, Linderholm K, Engberg G. Erhardt S, et al. Physiol Behav. 2007 Sep 10;92(1-2):203-9. doi: 10.1016/j.physbeh.2007.05.025. Epub 2007 May 21. Physiol Behav. 2007. PMID: 17573079 - Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia.
Nilsson LK, Linderholm KR, Engberg G, Paulson L, Blennow K, Lindström LH, Nordin C, Karanti A, Persson P, Erhardt S. Nilsson LK, et al. Schizophr Res. 2005 Dec 15;80(2-3):315-22. doi: 10.1016/j.schres.2005.07.013. Epub 2005 Aug 25. Schizophr Res. 2005. PMID: 16125901 - Kynurenic acid and schizophrenia.
Erhardt S, Schwieler L, Engberg G. Erhardt S, et al. Adv Exp Med Biol. 2003;527:155-65. doi: 10.1007/978-1-4615-0135-0_18. Adv Exp Med Biol. 2003. PMID: 15206728 - Kynurenic Acid in Schizophrenia: A Systematic Review and Meta-analysis.
Plitman E, Iwata Y, Caravaggio F, Nakajima S, Chung JK, Gerretsen P, Kim J, Takeuchi H, Chakravarty MM, Remington G, Graff-Guerrero A. Plitman E, et al. Schizophr Bull. 2017 Jul 1;43(4):764-777. doi: 10.1093/schbul/sbw221. Schizophr Bull. 2017. PMID: 28187219 Free PMC article. Review. - Bridging the gap between the immune and glutamate hypotheses of schizophrenia and major depression: Potential role of glial NMDA receptor modulators and impaired blood-brain barrier integrity.
Steiner J, Bogerts B, Sarnyai Z, Walter M, Gos T, Bernstein HG, Myint AM. Steiner J, et al. World J Biol Psychiatry. 2012 Oct;13(7):482-92. doi: 10.3109/15622975.2011.583941. Epub 2011 Jun 28. World J Biol Psychiatry. 2012. PMID: 21707463 Review.
Cited by
- Transport of Kynurenic Acid by Rat Organic Anion Transporters rOAT1 and rOAT3: Species Difference between Human and Rat in OAT1.
Uwai Y, Hara H, Iwamoto K. Uwai Y, et al. Int J Tryptophan Res. 2013;6:1-6. doi: 10.4137/IJTR.S11206. Epub 2013 Feb 17. Int J Tryptophan Res. 2013. PMID: 23467467 Free PMC article. - Glutamate and schizophrenia: beyond the dopamine hypothesis.
Coyle JT. Coyle JT. Cell Mol Neurobiol. 2006 Jul-Aug;26(4-6):365-84. doi: 10.1007/s10571-006-9062-8. Epub 2006 Jun 14. Cell Mol Neurobiol. 2006. PMID: 16773445 Review. - Developmental Exposure to Kynurenine Affects Zebrafish and Rat Behavior.
Marszalek-Grabska M, Gawel K, Kosheva N, Kocki T, Turski WA. Marszalek-Grabska M, et al. Cells. 2023 Sep 6;12(18):2224. doi: 10.3390/cells12182224. Cells. 2023. PMID: 37759447 Free PMC article. - Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia.
Young JW, Powell SB, Risbrough V, Marston HM, Geyer MA. Young JW, et al. Pharmacol Ther. 2009 May;122(2):150-202. doi: 10.1016/j.pharmthera.2009.02.004. Epub 2009 Mar 6. Pharmacol Ther. 2009. PMID: 19269307 Free PMC article. Review. - Pharmacological manipulation of kynurenic acid: potential in the treatment of psychiatric disorders.
Erhardt S, Olsson SK, Engberg G. Erhardt S, et al. CNS Drugs. 2009;23(2):91-101. doi: 10.2165/00023210-200923020-00001. CNS Drugs. 2009. PMID: 19173370 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical